Searched for
SANOFI DUPIXENT
Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...- EU approves Sanofi's Dupixent for 'smoker's lungs'Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significa...
- Sanofi looks for accelerated growth in India; plans fast-tracking of product pipelineSanofi, a leading French pharmaceutical company, aims to expand its presence in the Indian market by introducing new drugs, enhancing local...
- Sanofi plans to launch 1 or 2 products in India every yearSanofi prioritizes the Indian market, focusing on diabetes, consumer health, and innovation. With a strategic shift under Hrosz's leadershi...
- Sanofi trial failure ends development of breast cancer treatment amcenestrantA trial dubbed AMEERA-5, which was testing amcenestrant on women with newly-diagnosed advanced breast cancer, was stopped early because an ...
- European shares join global rally; Russia-Ukraine talks in focusThe pan-European STOXX 600 index climbed 0.8%, extending gains to a third straight session, as a sell-off in bonds continued.
- Sanofi and Regeneron's eczema drug gets FDA approvalThe FDA approved Dupixent (dupilumab), is the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis.
Load More